Clinical relevance of antimicrobial susceptibility testing

  • S. M. Finegold
Current Topic: Review


In recent years, significant resistance to antimicrobial agents has been encountered among certain anaerobic bacteria. Susceptibility patterns vary from region to region, but even within a given region susceptibility is not always predictable. Initially, therapy of mixed anaerobic infections must be empirical, based on the nature of the infection, the usual flora of such infections, anticipated modification of this flora by pathophysiologic processes or prior antimicrobial therapy, and evaluation of Gram stains from appropriate specimens. If the infection does not respond well or the patient requires long-term therapy, antimicrobial susceptibility testing may be indicated in order to provide optimum therapy. Susceptibility testing is also indicated for determination of the usual patterns in a particular hospital, for monitoring geographical patterns, and to determine the activity of new antimicrobial agents.


Internal Medicine Clinical Relevance Antimicrobial Agent Susceptibility Testing Antimicrobial Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Heseltine PNR, Appleman MD, Leedom JM Epidemiology and susceptibility of resistantBacteroides fragilis group organisms to new β-lactam antibiotics. Reviews of Infectious Diseases 1984, 6, Supplement 1: 254–258.Google Scholar
  2. 2.
    Nord CE, Olsson-Lilijquist B Anaerobic bacteria and beta-lactam antibiotics. Scandinavian Journal of Infectious Diseases 1984, 42, Supplementum: 72–82.PubMedGoogle Scholar
  3. 3.
    Cuchural GJ Jr, Snydman DR, McDermott L, Iannini PB, Hill GB, Cleary TJ, O'Keefe JP, Pierson CL, Rihs JD, Finegold SM Antimicrobial susceptibility patterns of theBacteroides fragilis group in the United States, 1989. Clinical Therapeutics 1992, 14: 122–136.PubMedGoogle Scholar
  4. 4.
    Yee MH, Guiney DG, Hasegawa P, Davis CE The clinical significance of clindamycin-resistantBacteroides fragilis. Journal of the American Medical Association 1982, 248: 1860–1863.CrossRefPubMedGoogle Scholar
  5. 5.
    Johnson CC, Reinhardt JF, Edelstein MAC, Mulligan ME, George WL, Finegold SM Bacteroides gracilis, an important anaerobic bacterial pathogen. Journal of Clinical Microbiology 1985, 22: 799–802.PubMedGoogle Scholar
  6. 6.
    National Committee for Clinical Laboratory Standards Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved standard M11-A2. NCCLS, Villanova, PA, 1990.Google Scholar
  7. 7.
    Wexler HM, Finegold SM Antimicrobial resistance inBacteroides. Journal of Antimicrobial Chemotherapy 1987, 19: 143–146.Google Scholar
  8. 8.
    Sutter VL, Citron DM, Edelstein MAC, Finegold SM Wadsworth anaerobic bacteriology manual. Star Publishing, Belmont, CA, 1985, p. 79–90.Google Scholar
  9. 9.
    Wexler HM, Molitoris E, Jashnian F, Finegold SM Comparison of spiral gradient and conventional agar dilution for susceptibility testing of anaerobic bacteria. Antimicrobial Agents and Chemotherapy 1991, 35: 1196–1202.PubMedGoogle Scholar
  10. 10.
    Citron DM, Ostovari MI, Karlsson A, Goldstein EJC Evaluation of the E test for susceptibility testing of anaerobic bacteria. Journal of Clinical Microbiology 1991, 29: 2197–2203.PubMedGoogle Scholar
  11. 11.
    Bartlett JG, Sutter VL, Finegold SM Treatment of anaerobic infections with lincomycin and clindamycin. New England Journal of Medicine 1972, 287: 1006–1010.PubMedGoogle Scholar
  12. 12.
    George WL, Kirby BD, Sutter VL, Wheeler LA, Mulligan ME, Finegold SM Intravenous metronidazole for treatment of infections involving anaerobic bacteria. Antimicrobial Agents and Chemotherapy 1982, 21: 441–449.PubMedGoogle Scholar
  13. 13.
    Goldstein EJC, Lewis RP, Sutter VL, Finegold SM Erythromycin for anaerobic pleuropulmonary and soft-tissue infections. Journal of the American Medical Association 1979, 242: 435–438.CrossRefPubMedGoogle Scholar
  14. 14.
    Heseltine PNR, Busch DF, Meyer RD, Finegold SM Cefoxitin: clinical evaluation in thirty-eight patients. Antimicrobial Agents and Chemotherapy 1977, 11: 427–434.PubMedGoogle Scholar
  15. 15.
    Kirby BD, Busch DF, Citron DM, Finegold SM Cefoxitin for treatment of infections due to anaerobic bacteria. Reviews of Infectious Diseases 1979, 1: 113–116.PubMedGoogle Scholar
  16. 16.
    Klein RA, Busch DF, Wilson SE, Flora DJ, Finegold SM Doxycycline in abdominal surgery. Journal of the American Medical Association 1977, 238: 1933–1935.CrossRefPubMedGoogle Scholar
  17. 17.
    Bryan CS, Reynolds KL, Kirkhart B, Brown JJ Bacteroides bacteremia. Analysis of 142 episodes from one metropolitan area. Archives of Surgery 1984, 119: 894–898.PubMedGoogle Scholar
  18. 18.
    Chow AW, Guze LB Bacteroidaceae bacteremia: clinical experience with 112 patients. Medicine (Baltimore) 1974, 53: 93–126.PubMedGoogle Scholar
  19. 19.
    Mathias RG, Harding GK, Gurwith MJ, Stiver HG, Sigurdson E, Gratton CA, Ronald AR Bacteremia due toBacteroidaceae: a review of 92 cases. Journal of Infectious Diseases 1977, 135, Supplement: 69–73.Google Scholar
  20. 20.
    Nobles ER Jr Bacteroides infections. Annals of Surgery 1973, 177: 601–606.PubMedGoogle Scholar
  21. 21.
    Tally FP Factors affecting antimicrobial agents in an anaerobic abscess. Journal of Antimicrobial Chemotherapy 1978, 4: 299–302.PubMedGoogle Scholar
  22. 22.
    Finegold SM, andthe National Committee for Clinical Laboratory Standards Working Group on Anaerobic Susceptibility Testing Susceptibility testing of anaerobic bacteria. Journal of Clinical Microbiology 1988, 26: 1253–1256.PubMedGoogle Scholar

Copyright information

© Friedr. Vieweg & Sohn Verlagsgesellschaft mbH 1992

Authors and Affiliations

  • S. M. Finegold
    • 1
    • 2
  1. 1.Research Service (W151)VA Medical Center West Los AngelesLos AngelesUSA
  2. 2.Department of Medicine, and Department of Microbiology and ImmunologyUCLA School of MedicineLos AngelesUSA

Personalised recommendations